{
  "ticker": "AMLX",
  "company_name": "Amylyx Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04987671",
      "title": "Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS",
      "status": "UNKNOWN",
      "phase": "PHASE1, PHASE2",
      "condition": "ALS",
      "start_date": "2021-08-05",
      "completion_date": "2023-09",
      "enrollment": 0,
      "sponsor": "Amylyx Pharmaceuticals Inc."
    },
    {
      "nct_id": "NCT05676034",
      "title": "AMX0035 in Adult Patients With Wolfram Syndrome",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Wolfram Syndrome",
      "start_date": "2023-03-03",
      "completion_date": "2026-12-31",
      "enrollment": 0,
      "sponsor": "Amylyx Pharmaceuticals Inc."
    },
    {
      "nct_id": "NCT03488524",
      "title": "Open Label Extension Study of AMX0035 in Patients With ALS",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Amyotrophic Lateral Sclerosis, ALS",
      "start_date": "2018-03-29",
      "completion_date": "2021-03-01",
      "enrollment": 0,
      "sponsor": "Amylyx Pharmaceuticals Inc."
    },
    {
      "nct_id": "NCT06122662",
      "title": "AMX0035 and Progressive Supranuclear Palsy",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism",
      "start_date": "2023-12-21",
      "completion_date": "2029-11-30",
      "enrollment": 0,
      "sponsor": "Amylyx Pharmaceuticals Inc."
    },
    {
      "nct_id": "NCT06665165",
      "title": "AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "ALS",
      "start_date": "2025-04-07",
      "completion_date": "2027-10",
      "enrollment": 0,
      "sponsor": "Amylyx Pharmaceuticals Inc."
    },
    {
      "nct_id": "NCT03127514",
      "title": "AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases, Spinal Cord Diseases, TDP-43 Proteinopathies, Nervous System Diseases, Central Nervous System Diseases",
      "start_date": "2017-06-22",
      "completion_date": "2019-11-24",
      "enrollment": 0,
      "sponsor": "Amylyx Pharmaceuticals Inc."
    },
    {
      "nct_id": "NCT04516096",
      "title": "A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)",
      "status": "COMPLETED",
      "phase": "PHASE2, PHASE3",
      "condition": "Amyotrophic Lateral Sclerosis",
      "start_date": "2020-11-22",
      "completion_date": "2023-01-31",
      "enrollment": 0,
      "sponsor": "Amylyx Pharmaceuticals Inc."
    },
    {
      "nct_id": "NCT05286372",
      "title": "An Intermediate Size Expanded Access Protocol of AMX0035 for ALS",
      "status": "APPROVED_FOR_MARKETING",
      "phase": "",
      "condition": "Amyotrophic Lateral Sclerosis",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Amylyx Pharmaceuticals Inc."
    },
    {
      "nct_id": "NCT06747468",
      "title": "Avexitide for Treatment of Post-Bariatric Hypoglycemia",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Post Bariatric Hypoglycemia",
      "start_date": "2025-04-29",
      "completion_date": "2026-10",
      "enrollment": 0,
      "sponsor": "Amylyx Pharmaceuticals Inc."
    },
    {
      "nct_id": "NCT03533257",
      "title": "Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Alzheimer Disease",
      "start_date": "2018-09-14",
      "completion_date": "2020-11-06",
      "enrollment": 0,
      "sponsor": "Amylyx Pharmaceuticals Inc."
    }
  ],
  "summary": {
    "total_trials": 12,
    "by_phase": {
      "PHASE1, PHASE2": 1,
      "PHASE2": 4,
      "PHASE2, PHASE3": 2,
      "PHASE1": 1,
      "": 1,
      "PHASE3": 3
    },
    "by_status": {
      "UNKNOWN": 1,
      "ACTIVE_NOT_RECRUITING": 3,
      "COMPLETED": 5,
      "RECRUITING": 2,
      "APPROVED_FOR_MARKETING": 1
    },
    "active_trials": 5,
    "completed_trials": 5,
    "conditions": [
      "ALS",
      "Alzheimer Disease",
      "Amyotrophic Lateral Sclerosis",
      "Amyotrophic Lateral Sclerosis, ALS",
      "Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases, Spinal Cord Diseases, TDP-43 Proteinopathies, Nervous System Diseases, Central Nervous System Diseases",
      "Post Bariatric Hypoglycemia",
      "Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism",
      "Wolfram Syndrome"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:16:18.765047",
    "search_query": "Amylyx Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Amylyx+Pharmaceuticals,+Inc."
  }
}